Extracorporeal carbon dioxide removal (ECCO2R) therapy in COPD and ARDS patients with severe hypercapnic respiratory failure. A retrospective case-control study.

Abstract

Background/aim: Treatment of severe hypercapnic respiratory failure (HRF) has some challenges in patients with chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS), especially when lung protective ventilation (LPV) strategies are required. Extracorporeal CO2 removal (ECCO2R) therapy is an emerging option to manage hypercapnia while allowing LPV in these cases. However, further data on ECCO2R use are still needed to clear recommendations.

Materials and methods: This study was conducted on patients admitted to intensive care unit (ICU) between Jan 1st, 2016 to Dec 31st, 2019. The medical records were retrospectively scanned in institutional software database. Patients who were received invasive mechanic ventilation (iMV) support due to severe HRF related to COPD or ARDS were included into analyses. Patients were grouped according to treatment approaches as that ECCO2R therapy in addition to conventional treatments and conventional treatments alone (controls). Groups were compared for 28-day survival, iMV duration and length of stay (LOS).

Results: ECCO2R therapy was noted in 75 of the cases among included 395 patients (COPD n= 256, ARDS n= 139) out of scanned 1715 medical records. The survival rate of ECCO2R patients was 68% and significantly higher than 58% survival rate of controls (p= 0.025), with relative risk reduction (RRR)= 0.16, absolute risk reduction (ARR)= 0.10, number need to treat (NNT)= 10, and odds ratio (OR)= 1.5. In addition, iMV duration (12.8 ± 2.6 vs. 17.1 ± 4.9 days, p= 0.007) and LOS (16.9 ± 4.1 vs. 18.9 ± 5.5
days, p = 0.032) were significantly shorter than controls. Repeated measure analyses showed that LPV settings were successfully provided by 72 hours of ECCO2R therapy. Subgroup analyses according to diagnoses of COPD and ARDS also favored ECCO2R.

**Conclusion:** ECCO2R therapy significantly improved survival, iMV duration and LOS in patients with severe HRF due to COPD or ARDS, and successfully provided LPV approaches. Further studies are needed to assess promising benefits of ECCO2R therapy.

**Key words:** Extracorporeal carbon dioxide removal, ECCO2R, hypercapnic respiratory failure, artificial membranes, survival, intensive care

1. **Introduction**

Hypercapnic respiratory failure is defined as a condition that plasma pH < 7.35 and partial arterial carbon dioxide (CO2) pressure (PaCO2) > 49 mmHg [1]. In more severe cases (pH < 7.25 and PCO2 > 60 mmHg), when persisted against attempts of medical therapy and non-invasive ventilation, invasive mechanical ventilation (iMV) support and intensive care unit (ICU) admission is required [1, 2]. Severe hypercapnia, whether associated with chronic obstructive pulmonary disease (COPD) or acute respiratory distress syndrome (ARDS), is an independent risk factor for patient mortality [3]. In addition, iMV support, used in treatment of severe hypercapnia, has its own consequences such as ventilatory associated pneumonia, ventilator-induced lung injury (VILI), extubation failure and prolonged intubation, iMV dependence etc. In recent decades, the lung protective ventilation (LPV) concept (low tidal volume and pressure-limited ventilation) has been presented with more favorable outcomes than traditional ventilation approaches in patients with respiratory failure [4]. LPV has been reported to decreased VILI, facilitated extubation and improved clinical outcomes [5].
However, LPV has an undesired consequence, progressing hypercapnia [5]. In order to break this deadly vicious cycle, some clinicians have proposed removing excessive CO2 by an adjunct extracorporeal device. It was a former concept, first introduced by Kobolow and Gattinoni almost 40 years ago and has re-gained attention [6-8]. This extracorporeal carbon dioxide removal (ECCO2R) technic can be described as that CO2 is removed by an attached artificial lung while oxygen delivered through the natural lung. Results of preliminary studies on accountability of ECCO2R therapy have exceeded the clinical expectations [2, 9-14]. However, ECCO2R has been a rescue treatment option in patients with severe hypercapnic respiratory failure until recent years [13-16].

The later technological improvements and experiences in ECCO2R have provided promising clinical outcomes with lower adverse event rates [11-14, 17]. Finally, ECCO2R therapy has been recommended in the treatment of ARDS and acute exacerbations of COPD to apply LPV while managing hypercapnia, and to achieve targets of pH > 7.30, respiratory rate (RR) < 20-25 breaths/min., driving pressure (ΔP) < 14 cmH2O and plateau pressure (Pplat) < 25 cmH2O, by the European Consensus Report [18]. Some prospective feasibility studies have still been recruiting cases (i.e., The REXECOR trial - NCT02965079, The REST trial - NCT02654327). However, further feasibility studies and more evidence-based data are required to make stronger recommendations.

ECCO2R has been successfully used in treatment of patients with severe HRF for about five years in our ICU. We conducted a retrospective data analyze of our patients who were received ECCO2R therapy. The objective was to elucidate and document favorable effects of ECCO2R therapy against conventional treatments alone at respect of 28-day survival, iMV duration and ICU length-of-stay (LOS).
2. Materials and methods

This retrospective study was conducted in Trakya University Training and Research Hospital, in Turkey, between October 5th – November 27th, 2020. The approval was received from Bioethical Board of Trakya University (no=2020/199 – 09/05). Informed consent for “processing and publishing personal medical data for scientific purposes” has been obtained at ICU admissions (institutional policy) from patients or legally authorized surrogates when patients were intubated, ventilated, unconscious or sedated.

2.1 Case Definitions

The case definitions were based on those “2016 British Thoracic Society / Intensive Care Society (BTS / ICS) Guideline for the ventilatory management of acute hypercapnic respiratory failure in adults” for hypercapnic respiratory failure, “2019 The Global Initiative for Chronic Obstructive Lung Disease (GOLD)” for COPD and “2012 The Berlin Definition” for ARDS [1, 19, 20].

2.2 ECCO2R indications

According to practice instructions of our clinic, ECCO2R therapy has been applied in patients who met all requirements of these five-criteria; (1) persisting severe hypercapnic respiratory acidosis (pH < 7.15) despite optimized attempts of iMV for more than 3 hours, (2) lung protective ventilation was required but hypercapnia was undesirable or contraindicated, (3) no contraindications for canulation and systemic anticoagulation, (4) hemodynamic status was manageable, (5) the underlying disease was reversible or no markers of poor short-term prognosis.

2.3 ECCO2R procedure

Veno-venous Decap® system (Hemodec, Salerno, Italy) with a small membrane lung (0.3 to 1.35 m²) connected in series with a roller pump and low flow rates (< 500 ml/min) was
used for ECCO2R therapy [5, 21, 22]. Vascular accesses were provided by percutaneous inserted double-lumen catheters into internal jugular or femoral vein. Unfractionated heparin continuous infusion protocol was used according to activated partial thromboplastin time readings as recommended.

2.4 Patients’ selection

The medical records of patients admitted to ICU between Jan 1st, 2016 to Dec 31st, 2019 were retrospectively scanned in institutional software database. Diagnoses were searched by ICD-10 codes (J96, J44, J80). All patients who required iMV support due to hypercapnic respiratory failure related to COPD or ARDS diagnoses were included. Patients detected with both of COPD and ARDS diagnoses were excluded to avoid case-mix bias in subgroup comparisons.

2.5 Comparisons

Patients were grouped according to treatment approaches as they were received ECCO2R therapy in addition to conventional treatments (cases), and conventional treatments alone and not received ECCO2R (controls). Case and control groups were compared for 28-day survival, iMV duration and ICU LOS. Figure 1. The changes in clinical and laboratory parameters after 72 hours of procedure were also analyzed. Finally, a strict 1:1 matching was processed to gain a precise aspect and to re-test hypothesis. Additional exclusion criteria were re-defined as; patients with age < 18 and 90 <, obstetrics, hematologic and oncologic diagnoses, acute decompensated heart failure, acute coronary syndromes, profound distributive shock and ECCO2R therapy less than 72 hrs. To assure a better comparability, ECCO2R patients were best 1:1 matched with controls by Sequential Organ Failure Assessment (SOFA) scores corresponding to their disease severity status. Unmatched control patients were excluded, while we downsized
the sample. Resulting $COPD_{ECCO2R}:COPD_{Control}$ and $ARDS_{ECCO2R}:ARDS_{Control}$ subgroups were within compared for survival. This matching process was presented in Figure 2.

The operators were blinded for outcomes throughout selection, allocation, matching, and exclusion procedures, provided by software concealment.

2.6 Data collection

Patients’ gender, age, SOFA scores, and total iMV duration, ICU LOS and 28-day survival status were collected. In order to evaluate improvements by ECCO2R procedure; arterial blood gas (ABG) parameters (pH, PaCO2, PaO2) and ventilatory parameters (P/F ratio: PaO2/FiO2 ratio, PEEP; positive end expiratory pressure, Pplat, ΔP[driving pressure]= Pplat - PEEP, Ttv/PBW; tidal volume/predicted body weight) were noted at the initiation ($t=0$) and at the 72nd hours of therapy ($t=72$). Clinical (RR; respiratory rate, HR; heart rate, MAP; mean arterial pressure) and laboratory parameters (hemoglobin, PLT, PT-INR, aPTT-ratio) were also collected to detect any probable deteriorations. Total ECCO2R duration, the mean pump flow and sweep gas flow rates were recorded.

Any severe adverse effect related to ECCO2R procedure (worsening hypoxemia, hemolysis, anti-coagulation or canula related bleeding, hematoma, heparin-induced thrombocytopenia, thrombosis, or mechanical events) were checked within daily progress records.

2.7 Outcomes

The primary outcome of this study was to assess advantages of ECCO2R therapy over conventional treatment alone in terms of 28-day ICU survival, iMV duration and LOS.

Statistical Analyses

A power analysis was performed with a free software (G*Power© ver3.1.9.4, Germany) before the data collection, that at least 44 ECOO2R patients were required in order to gain
an approximated power of 80% with 0.5 effect size, 0.05 alpha error probability, and 2.0
critical t-value in two tailed calculations. Collected data management and analyses were
performed using statistical software program SPSS (IBM® SPSS® Statistics ver25, Ill,
USA, 2017). Comparability of the data was provided by stratum and weighting.
Continuous variables were reported as median and inter quartile range (IQR), mean ±
standard deviation (SD) and categorical variables as counts and proportions when
appropriate. Comparison of proportions was made using Chi-square test. Data at different
times during ECCO2R (repeated measures) were compared using analysis of variance
(ANOVA). When significance (p ≤ 0.05) obtained after 72 h of ECCO2R, was compared
with previous using paired t test (adjusted), and by Bonferroni corrections. The
conditional analyses were used rather than unconditional since strata was relatively small.
The contingency tables were formed. Relative and absolute risk reductions ((RRR and
ARR), number need to treat (NNT) and odds ratios (OR) were calculated. All P values
were two-tailed and values < 0.05 (CI of 95%) were deemed as significant.

3. Results

Medical records of 1715 patients were scanned. After exclusion of 164 patients with both
of COPD and ARDS diagnoses, 395 patients who required iMV support due to COPD
(n= 256) or ARDS (n= 139) were assigned into the study. The main reason for COPD
admissions was acute and severe exacerbation of disease (94%). ARDS was due to
primary pulmonary insults in 74% of the cases.

General characteristics, admission SOFA scores, ABG and ventilatory parameters, iMV
support duration, LOS and 28-day survival status of patients were presented in Table 1.
ECCO2R therapy was noted in 75 of 395 patients. ECCO2R group 28-day survival rate
was 68% and significantly higher than 58% survival rate of controls (p= 0.025). In
subgroup analyses, survival rates of COPD (65%) and ARDS (73%) patient who received 
ECCO2R therapy were higher than control COPD (55%) and ARDS (65%) patients. In 
addition to this, ECCO2R therapy significantly shortened iMV duration and ICU LOS in 
both COPD and ARDS patients. Calculated total survival OR was found below 2.0 (1.5 
(0.9 – 2.6)), but NNT (NNT= 10), relative risk reduction (0.16 (0.03 – 0.39) and absolute 
risk reduction rates (0.10 (0.02 – 0.21)) were promising for ECCO2R therapy group, as 
presented in Table 2.

Arterial blood gas, ventilatory, clinical and laboratory parameters recorded at t= 0 and t= 
72 of ECCO2R procedure, and ECCO2R duration (days), pump flow and sweep gas flow 
rates were presented in Table 3. pH, PaO2 and PaCO2 levels of control group were not 
significantly improved at t=72. On the other hand, ECCO2R therapy significantly 
ameliorated patients ABG parameters. Significant improvement in mean pH (p= 0.048) 
and PaO2 (p= 0.032), and significant reduction in mean PaCO2 (p= 0.027) levels were 
provided at t= 72 of ECCO2R treatment. While ventilatory parameters were improved 
and facilitated LPV, the mean P/F ratio (p= 0.008), Pplat (p= 0.035) and driving pressure 
(p= 0.040) were significantly improved in both COPD and ARDS patients. A significant 
change in Tv/PBW levels were not detected that were about 7 ml/kg throughout 72 hrs. 
Mean PEEP levels were improved in COPD (p= 0.040) patients. While in ARDS patients, 
required PEEP levels were not changed in 72 hrs. possible due to prolonged need for 
higher PEEP levels in those patients.

There were no detected significant change or deterioration in patients’ mean RR, HR, and 
MAP parameters through 72 hrs. of ECCO2R therapy. The mean hemoglobin and PLT 
levels were found lower at t= 72 but those were not clinically remarkable nor required 
transfusion, as in daily progress records. aPPT ratio was 2× longer due to provided
heparin anti-coagulation protocol, at \( t = 72 \). No severe adverse effects related to procedure were mentioned in the records.

At the final step, we re-tested the hypothesis with a strict 1:1 matching by SOFA disease severity score. While 44 patients from ECCO2R and 75 patients from control group were excluded by additionally re-defined criteria, downsized the case and control samples to 31/31 (COPD n= 20/20, ARDS n= 11/11). Figure 2. Total survival rates were in favor of ECCO2R patients (68%) against controls (56%). In subgroup comparisons, survival rates of ECCO2R treated COPD (75%) and ARDS (55%) patients were significantly higher than control COPD (50%) and ARDS (18%). The contingency calculations for matched comparisons were presented in Table 4. Although resulted sample size was highly downsized by this strict matching, total survival OR \((1.7 (0.8 – 3.7))\) and NNT \((NNT=8)\) values strikingly favored beneficial effect of ECCO2R therapy.

4. Discussion

Recently, ECCO2R therapy has been more frequently used in treatment of patients with severe respiratory failure. Especially in conditions such as ARDS and acute exacerbations of COPD that LPV is required and lifesaving. ECCO2R facilitates settings of lower respiratory rates, and lower driving and plateau pressures, while successfully removing excess CO2. Additionally, removal of excess CO2 also would help to normalize acidotic pH levels and improve manageability of distressed conditions.

However, in a previous systematic review that included two RCT and 12 observational studies on ARDS patients \((n= 495)\), ECCO2R therapy was not found advantageous in terms of patient survival and LOS [23]. On the contrary, our study results showed a significant survival and LOS benefit with ECCO2R therapy. We assumed that difference
was related to mixed type of diagnoses in our study, in which ARDS patients constituted
the one third of the sample. It was also reasonable to expect lower survival rates in ARDS
patients than COPD. Nevertheless, subgroup analyses of our ARDS patients presented
higher survival benefit with ECCO2R. In addition, iMV duration and ICU LOS were
significantly shorter. Then, a supportive systematic review to our assumptions, in 2015
by Sklar et al., that included ten case series of ECCO2R therapy in COPD patients with
hypercapnic respiratory failure (n= 87), showed that ECCO2R therapy assisted successful
extubation (53%) with lower mortality rates, and improved ABG parameters [24]. The
patient characteristics of Sklar’s sample were more similar to our study patients, hence
we assume those results were more comparable than previous.

Eventually, the ECLAIR study in 2016 was published that ECCO2R therapy was
successful to avoid iMV and shortened iMV duration, but not LOS nor improved survival
[15]. This was a multicentric case-control (n= 25/25) study that compared hypercapnic
respiratory failure patients, and especially focused on avoidance of intubation and iMV
by ECCO2R, rather than survival benefits. These results were valuable but should be
cautiously evaluated in regards of small sample size for generalizability. Another
feasibility study on ECCO2R therapy in ARDS patients (n= 15) by Fanelli et al., reported
significant improvements in clinical, ventilatory and ABG parameters similar to our
results. They underlined the efficiency of ECCO2R in providing LPV, that was accounted
as one of the most effective approaches in ARDS patient [16]. Fanelli’s study ARDS
sample was also quite similar to our ARDS patients in terms of age, gender, and SOFA
scores, and consistent with our results.

Here, we also presented that 72 hours of ECCO2R procedure significantly improved ABG
and ventilatory parameters in both COPD and ARDS patients and safely provided LPV
settings. Thereby, we assumed this was the main influential factor for higher survival rates. Another supportive study by Hilty et al. assessed 20 ARDS and COPD patients with hypercapnic respiratory failure, although a conventional controls arm was not present, also reported that ECCO2R therapy was safe and provided LPV, [25]. Another similar retrospective observational ECCO2R study by Moss et al. that included 14 patients (COPD n= 5, ARDS n= 9) with hypercapnic respiratory failure, compared the data of survivors vs. non-survivors [26]. The mean pH levels were successfully improved, and the survival rate was 71% (10/14), in concordance with our results. However, the average LOS (31.9 vs. 7) and iMV (53 vs. 8.5) were longer in survivors than non-survivors. That discrepancy could be due to lack of a conventional treatment control group for a coherent comparison in that study.

However, in 2017, Taccone et al. reviewed six studies on ECCO2R therapy in COPD and ARDS patients (n= 142) those were published between 1994 – 2015, and concluded that evidence of survival benefit was moderate, yet [7]. Although inconclusive data have been published until 2018, we believe these should be considered at respect of that most studies were case series, not homogenous with possible case-mix bias issues and lack of control groups. As of 2018, more promising results have given to rise. A UK Register study on severe respiratory failure patients (n= 60) reported significant benefits of ECCO2R treatment on ABG and ventilatory parameters, without any clinical deterioration, however not showed an exact benefit for survival [27]. Proceeded by Schmidt et al., 20 ARDS patients treated by ECCO2R and safely enhanced LPV with significantly higher survival rates (85%) [14]. Finally, recent SUPERNOVA study on feasibility of ECCO2R therapy in 95 ARDS patients reported a significantly high cumulative 28-day survival rates (73%) [13]. In addition, a recently published retrospective data of 11 respiratory failure patients
by Grasselli et al. reported that low-flow VV-ECCO2R successfully improved ABG parameters and reduced ventilatory load, with a 71% survival rate in COPD patients [28]. The results of our study have supported and in concordance with accumulated data as of 2018, but not previous ones [13, 14, 28]. A positive attitude has been rising on extracorporeal therapies by 2018. Technological advancements, procedural improvements, and easier accessibility of ECCO2R should has contributed to this trend. Promising benefits of ECCO2R has gained a wider recognition and concern. Recently, the first European consensus encouraging ECCO2R therapy in ICU has been published by Combes et al., based on accumulated data that ARDS and COPD patients could benefit from ECCO2R [18]. As soon, we could anticipate that ECCO2R would be a part of conventional treatment protocols in severe ARDS and COPD patients.

Our study has number of limitations to be considered. The retrospective design was prone to recall and selection biases. The main analyses were depended on case-mix samples. The secondary analyses with strict matching provided a specific comparability but led high number of exclusions and downsized the sample. These could have produced exaggerated statistical significances. Finally, this study represents to our patient population and applicable to our settings, reasonably cannot be extrapolated to all settings and external validations are required for decisive evidence.

Conclusion

Results of our study supported that low-flow VV-ECCO2R therapy has a role in improving survival rates, iMV duration and LOS in patients with HRF due to COPD or ARDS. In addition, significant improvements in ABG and ventilation parameters while facilitating LPV have been achieved by ECCO2R therapy, with no marked clinical and
laboratory deteriorations. Further studies are required to assess that promising benefits of ECCO2R therapy.

Acknowledgement and/or disclaimers - none

References


Table 1. Presentation of COPD and ARDS patients’ general characteristics, SOFA scores, arterial blood gas and ventilatory parameters, iMV days, LOS and 28-day survival rates. Frequency, percentage, median - IQR, and mean±SD values were used as appropriate.

<table>
<thead>
<tr>
<th></th>
<th>TOTAL (n=395)</th>
<th>COPD (n=256)</th>
<th>ARDS (n=139)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ECCO2R (n=75)</td>
<td>Control (n=320)</td>
<td>p</td>
</tr>
<tr>
<td>n, male / female</td>
<td>41 / 34</td>
<td>186 / 134</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>63 (17 - 93)</td>
<td>66 (16 - 97)</td>
<td>ns</td>
</tr>
<tr>
<td>SOFA score</td>
<td>13 (8 - 17)</td>
<td>12 (7 - 16)</td>
<td>ns</td>
</tr>
<tr>
<td>ABG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>7.156±0.07</td>
<td>7.184±0.02</td>
<td>ns</td>
</tr>
<tr>
<td>PaCO2 (mmHg)</td>
<td>81±21</td>
<td>77±19</td>
<td>ns</td>
</tr>
<tr>
<td>PaO2 (mmHg)</td>
<td>61±6</td>
<td>59±7</td>
<td>ns</td>
</tr>
<tr>
<td>Ventilatory</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P/F ratio</td>
<td>89±11</td>
<td>92±12</td>
<td>ns</td>
</tr>
<tr>
<td>PEEP (cmH2O)</td>
<td>13±3</td>
<td>12±3</td>
<td>ns</td>
</tr>
<tr>
<td>Pplat (cmH2O)</td>
<td>36±6</td>
<td>34±7</td>
<td>ns</td>
</tr>
<tr>
<td>ΔP (cmH2O)</td>
<td>23±2</td>
<td>22±3</td>
<td>ns</td>
</tr>
<tr>
<td>Tv/PBW (ml/kg)</td>
<td>7±1</td>
<td>7±2</td>
<td>ns</td>
</tr>
<tr>
<td>Outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>iMV (days)</td>
<td>11 (8 - 19)</td>
<td>14 (7 - 22)</td>
<td>0.007</td>
</tr>
<tr>
<td>LOS (days)</td>
<td>17 (7 - 28)</td>
<td>26 (5 - 45)</td>
<td>0.032</td>
</tr>
<tr>
<td>n, survived / ex (%)</td>
<td>51 / 24 (68%)</td>
<td>187 / 133 (58%)</td>
<td>0.025</td>
</tr>
</tbody>
</table>

COPD; chronic obstructive pulmonary disease, ARDS; acute respiratory distress syndrome, SOFA score; sequential organ failure assessment score, iMV; invasive mechanic-ventilation duration, LOS; length of ICU stays, IQR; inter-quartile range, ABG; arterial blood gas, P/F; PaO2/FiO2 ratio, PEEP; positive end expiratory pressure, Pplat; plateau pressure, ΔP; (driving pressure) = Pplat - PEEP, Tv/BPW; tidal volume/predicted body weight, ECCO2R; extracorporeal CO2 removal.
Table 2. The 2x2 contingency table presenting 28-day survival statuses of ECCO2R vs conventional treated-alone COPD and ARDS patients, comparisons, and statistical calculations. Statistical p values, RRR, ARR and ORs with 95% CIs.

<table>
<thead>
<tr>
<th></th>
<th>Survived (n)</th>
<th>Ex (n)</th>
<th>p</th>
<th>RRR</th>
<th>ARR</th>
<th>OR</th>
<th>NNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL</td>
<td>ECCO2R</td>
<td>51 (68%)</td>
<td>24 (32%)</td>
<td>0.025</td>
<td>0.16</td>
<td>0.10</td>
<td>1.5</td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>187 (58%)</td>
<td>133 (42%)</td>
<td></td>
<td>(0.03 – 0.39)</td>
<td>(0.02 - 0.21)</td>
<td>(0.9 – 2.6)</td>
</tr>
<tr>
<td>COPD</td>
<td>ECCO2R</td>
<td>32 (65%)</td>
<td>17 (35%)</td>
<td>0.036</td>
<td>0.20</td>
<td>0.11</td>
<td>1.6</td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>113 (55%)</td>
<td>94 (45%)</td>
<td></td>
<td>(0.06 – 0.52)</td>
<td>(0.04 – 0.25)</td>
<td>(0.8 – 3.0)</td>
</tr>
<tr>
<td>ARDS</td>
<td>ECCO2R</td>
<td>19 (73%)</td>
<td>7 (27%)</td>
<td>0.042</td>
<td>0.12</td>
<td>0.08</td>
<td>1.4</td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>74 (65%)</td>
<td>39 (35%)</td>
<td></td>
<td>(0.02 – 0.46)</td>
<td>(0.03 – 0.12)</td>
<td>(0.6 – 3.7)</td>
</tr>
</tbody>
</table>

ECCO2R; extracorporeal CO2 removal, COPD; chronic obstructive pulmonary disease, ARDS; acute respiratory distress syndrome, RRR; relative risk reduction, ARR; absolute risk reduction, NNT; number need to treat, OR; odds ratio, CI; confidence intervals.
Table 3. ECCO2R procedure recordings at t=0 and t=72 hours of treatment; arterial blood gas, ventilatory, clinical and laboratory parameter comparisons.

Control group pH, PaCO2 and PaO2 levels were also presented, and no significant difference was noticed at t=72. Data were presented as mean±SD values, median - IQR, and statistical differences.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>TOTAL (n=75)</th>
<th>COPD (n=49)</th>
<th>ARDS (n=26)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>t=0</td>
<td>t=72</td>
<td>t=0</td>
</tr>
<tr>
<td><strong>ABG</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Case-pH</td>
<td>7.156±0.07</td>
<td>7.339±0.05</td>
<td>0.048</td>
</tr>
<tr>
<td>Control-pH</td>
<td>7.184±0.02</td>
<td>7.265±0.09</td>
<td>ns</td>
</tr>
<tr>
<td>Case-PaCO2 (mmHg)</td>
<td>81±21</td>
<td>53±9</td>
<td>0.027</td>
</tr>
<tr>
<td>Control-PaCO2 (mmHg)</td>
<td>77±19</td>
<td>71±16</td>
<td>ns</td>
</tr>
<tr>
<td>Case-PaO2 (mmHg)</td>
<td>61±6</td>
<td>82±8</td>
<td>0.032</td>
</tr>
<tr>
<td>Control-PaO2 (mmHg)</td>
<td>59±7</td>
<td>71±9</td>
<td>ns</td>
</tr>
<tr>
<td><strong>Ventilatory</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P/F ratio</td>
<td>89±11</td>
<td>150±53</td>
<td>0.008</td>
</tr>
<tr>
<td>PEEP (cmH2O)</td>
<td>13±3</td>
<td>12±3</td>
<td>0.050</td>
</tr>
<tr>
<td>Pplat (cmH2O)</td>
<td>36±6</td>
<td>29±3</td>
<td>0.035</td>
</tr>
<tr>
<td>AP (cmH2O)</td>
<td>23±2</td>
<td>17±3</td>
<td>0.040</td>
</tr>
<tr>
<td>Tv/PBW (ml/kg)</td>
<td>7±1</td>
<td>7±1</td>
<td>ns</td>
</tr>
<tr>
<td><strong>Clinical</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RR (min)</td>
<td>19±2</td>
<td>18±3</td>
<td>ns</td>
</tr>
<tr>
<td>HR (min)</td>
<td>117±13</td>
<td>113±13</td>
<td>ns</td>
</tr>
<tr>
<td>MAP (mmHg)</td>
<td>58±9</td>
<td>54±7</td>
<td>ns</td>
</tr>
<tr>
<td><strong>Laboratory</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>11.3±0.8</td>
<td>10.5±0.8</td>
<td>0.050</td>
</tr>
<tr>
<td>PLT (10^3/µ)</td>
<td>117±17</td>
<td>103±18</td>
<td>0.043</td>
</tr>
<tr>
<td>PT-INR</td>
<td>1.3±0.2</td>
<td>1.4±0.2</td>
<td>ns</td>
</tr>
<tr>
<td>aPTT ratio (sec.)</td>
<td>37±8</td>
<td>73±15</td>
<td>0.023</td>
</tr>
<tr>
<td><strong>ECCO2R</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECCO2R days</td>
<td>6 (4 - 9)</td>
<td>7 (4 - 9)</td>
<td>6 (4 - 8)</td>
</tr>
<tr>
<td>Pump flow (mL/min)</td>
<td>270 (190 - 420)</td>
<td>270 (180 - 420)</td>
<td>320 (210 - 450)</td>
</tr>
<tr>
<td>Sweep gas flow rate (L/min)</td>
<td>8 (6 - 11)</td>
<td>7 (6 - 10)</td>
<td>8 (6 - 12)</td>
</tr>
</tbody>
</table>
ECCO2R; extracorporeal CO2 removal, IQR; inter-quartile range, COPD; chronic obstructive pulmonary disease, ARDS; acute respiratory distress syndrome, ABG; arterial blood gas, P/F; PaO2/FiO2 ratio, PEEP; positive end expiratory pressure, Pplat; plateau pressure, ΔP; (driving pressure) = Pplat - PEEP, Tv/BPW; tidal volume/predicted body weight, RR; respiratory rate, HR; heart rate, MAP; mean arterial pressure, ns; non-significant.
Table 4. The 2x2 contingency table presenting 28-day survival statuses of ECCO2R vs conventional treated-alone COPD and ARDS patients, for 1:1 matching.

<table>
<thead>
<tr>
<th></th>
<th>Survived (n)</th>
<th>Ex (n)</th>
<th>p</th>
<th>RRR</th>
<th>ARR</th>
<th>OR</th>
<th>NNT</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOTAL</td>
<td>ECCO2R</td>
<td>21 (68%)</td>
<td>10 (32%)</td>
<td>0.018</td>
<td>0.22</td>
<td>0.12</td>
<td>1.7</td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>136 (56%)</td>
<td>109 (44%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD</td>
<td>ECCO2R</td>
<td>15 (75%)</td>
<td>5 (25%)</td>
<td>0.016</td>
<td>0.50</td>
<td>0.25</td>
<td>3.0</td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>10 (50%)</td>
<td>10 (50%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ARDS</td>
<td>ECCO2R</td>
<td>6 (55%)</td>
<td>5 (45%)</td>
<td>0.021</td>
<td>2.0</td>
<td>0.36</td>
<td>5.4</td>
</tr>
<tr>
<td></td>
<td>Control</td>
<td>2 (18%)</td>
<td>9 (82%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ECCO2R; extracorporeal CO2 removal, COPD; chronic obstructive pulmonary disease, ARDS; acute respiratory distress syndrome, RRR; relative risk reduction, ARR; absolute risk reduction, NNT; number need to treat, OR; odds ratio, CI; confidence intervals.
Figure 1. Study diagram representing allocations and comparisons.

ICU; intensive care unit, ECCO2R; extracorporeal CO2 removal, COPD; chronic obstructive pulmonary disease, ARDS; acute respiratory distress syndrome, Conv. Treat.; conventional treatment alone, Surv.; survival.
Figure 2. Diagram representing secondary re-test procedure. Additional exclusions and best 1:1 matching process.

ICU; intensive care unit, ECCO2R; extracorporeal CO2 removal, COPD; chronic obstructive pulmonary disease, ARDS; acute respiratory distress syndrome, Conv. Treat.; conventional treatment alone, Surv.; survival.